Interview

“You’ve got … to get outside of your comfort zone”

5 questions with Genentech’s Wayne Fairbrother
Laurel Oldach
Nov. 20, 2020

Wayne Fairbrother leads a department at Genentech tasked with validating disease-associated targets and determining whether they are feasible for drug development. The biophysicist, who was raised in New Zealand and has lived in California for decades, sat down virtually with ASBMB Today to talk about his career. The interview has been edited.

Fairbrother-Wayne-445x443.jpg

Name: Wayne Fairbrother

Current position: Director and senior staff scientist, Early Discovery Biochemistry, Genentech

Career path:

  • D.Phil., Oxford University, 1989
  • Postdoc: Scripps Research Institute
  • First job outside academia: Scientist, Genentech

Favorite molecule or protein: Bcl-2

How did you come to work at Genentech?

It's an interesting story. Genentech was looking to set up a protein nuclear magnetic resonance group back in the early 1990s. I applied for the position and, as many people do, got a polite "thank you, but no thank you" letter. Two or three months later I got a call from the director of protein engineering, who had gotten my name from one of their consultants, a senior person in protein NMR who I knew — and I got the job.

I like to tell that story to people looking for positions. You can get lost in the bureaucracy, especially nowadays when everything is computer searched, so having a network definitely helps.

Any other advice you often give?

I tell people going into industry the one thing I can guarantee is that in five years they'll be working on something completely different. Things progress and come in and out of favor for various reasons, whether it's science, strategic decisions or competition. So you need to be flexible.

That, and collaboration. You can't do anything without working with colleagues who have different expertise to put the pieces together and solve a problem. You've got to be prepared to get outside of your comfort zone.

How has Genentech changed in your time there?

The company has gotten bigger. In the early days we'd interact with everyone; now we're spread over a larger campus, and it's harder to know what's going on everywhere at all times. You need to be more proactive in keeping your finger on the pulse. Also, the pendulum has swung a little from basic discovery to more translational research. Of course, we're all about making therapeutics for unmet medical needs, so translation is critical.

Is there a project you're especially proud to have worked on?

There's a clear winner there: a collaboration with Abbot Labs (now AbbVie) and the Walter and Eliza Hall Institute in Australia that resulted in a treatment for chronic lymphocytic leukemia and acute myeloid leukemia. It's a molecule that specifically targets Bcl-2, which for a long time was considered undruggable. It was an exciting project — and it's always fun to meet patients who have benefited from something that you've touched. It reminds you why we do what we do.

Is there such a thing as an undruggable target?

I don't think there is. It may be true to say it's not druggable with the technology now, but technology is evolving. When a target is considered undruggable, it just means that we haven't discovered the way to drug it yet. That's the way I like to think.

(Would you like to suggest an ASBMB member who works in industry for a Five Questions interview? Send an email to ASBMB Today.)

 

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Featured jobs

from the ASBMB career center

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Industry

Industry highlights or most popular articles

‘We're all a bunch of weirdos doing our stuff’
Jobs

‘We're all a bunch of weirdos doing our stuff’

May 20, 2022

An interview with Charles Sanders, a research associate at XBiotech.

How Robert Langer failed repeatedly but kept going
Interview

How Robert Langer failed repeatedly but kept going

May 3, 2022

"They said I should give up, but I don’t like to give up," the pioneer in delivering mRNA to the body said.

'Anywhere you go, be ready to review your work'
Interview

'Anywhere you go, be ready to review your work'

April 29, 2022

Maria Grandoni is a scientist at PPD. She talked to our industry careers columnist about her work on the manufacturing and quality side of industry.

Ole Miss strikes $5M deal with company warned for claiming essential oils can cure COVID
News

Ole Miss strikes $5M deal with company warned for claiming essential oils can cure COVID

April 26, 2022

Companies have long sought to partner on research with public universities, which, starved for state funding, eagerly take private dollars.

‘Have faith in that training’
Interview

‘Have faith in that training’

March 18, 2022

Raghuvir Sengupta has been a biochemist for HP and is now a Pfizer postdoc. He talks about his work and how his graduate training prepared him for his industry career.

90% of drugs fail clinical trials
Editorial

90% of drugs fail clinical trials

March 12, 2022

Here’s one way researchers can select better drug candidates.